Intellia Therapeutics (NTLA) Return on Sales (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Return on Sales data on file, last reported at 0.13% in Q1 2026.

• On a quarterly basis, Return on Sales rose 3.0% year-over-year to 0.13% in Q1 2026; TTM through Mar 2026 was 0.09%, a 5.0% increase from a year earlier, with the FY2025 full-year figure at 0.2%, up 2.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.13%, down from 0.04% in the prior quarter.
• Over the last five years, Return on Sales for NTLA reached as high as 0.85% in Q4 2023 and fell as low as 0.31% in Q1 2022.
• Historically, Return on Sales has averaged 0.08% across 5 years, with a median of 0.13% in 2023.
• Across the five-year window, Return on Sales soared 145 bps in 2022 and tumbled 95 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.08% in 2022, then soared by 1165 bps to 0.85% in 2023, then tumbled by 112 bps to 0.1% in 2024, then soared by 59 bps to 0.04% in 2025, then plunged by 219 bps to 0.13% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.13% in Q1 2026, 0.04% in Q4 2025, and 0.16% in Q3 2025.